Thank you for your interest in Sygnature Discovery.
Sygnature Discovery is a leading independent integrated drug discovery and non-clinical services company. The team provides drug discovery services to find novel ways to fight incredibly serious diseases. Private equity-backed since by Five Arrows Principal Investments, we operate fully-enabled research facilities in Nottingham and Alderley Park, UK, which house over 400 research scientists (over 80% of whom hold a PhD). Additional offices are located in Cambridge, MA, and South San Francisco, CA, in the US.
Sygnature’s experienced ‘drug-hunters’ are interested in drastically improving outcomes for patients with serious diseases, discovering the foundations for the next generation of medicine. They have the professional skills and expertise required to undertake the most demanding of research programs, and drive them from target validation through hit identification, hit-to-lead and lead optimisation to pre-clinical development candidate.
Since 2011, 36 compounds, discovered by Sygnature for partners, have entered pre-clinical development. Twenty-one of these have progressed to clinical trials (Phases I, II and III).